Can VDPHL01 carry its male-trial momentum into women? Veradermics is about to show the data
See why Veradermics’ Study 207 female data could shape VDPHL01 dose selection, safety expectations and its Phase 3 clinical strategy.
Pharma & Biotech
Pharma & Biotech
Could Absci’s ABS-201 open a new biologic pathway for androgenetic alopecia treatment?
Absci’s interim ABS-201 data strengthen the early case for a long-acting PRLR antibody in androgenetic alopecia and AI-designed biologics.
Medical Devices & Diagnostics
Lumenis strengthens FoLix, ULTRApulse Alpha and Stellar M22 case with ASLMS data
Aesthetics needs stronger evidence. Lumenis is using ASLMS data to push lasers deeper into hair loss, skin and rhinophyma care.
Pharma & Biotech
Why the Veradermics hair loss trial is bigger than another aesthetics readout
Hair loss drugs are old, demand is huge, and Veradermics now faces the data test that could reset oral minoxidil’s commercial future.
Pharma & Biotech
Menopause-specific hair loss enters the clinical spotlight after KilgourMD trial data
KilgourMD’s phase II data challenges how menopause-related hair loss is studied and treated. See what changes and what clinicians will watch next.
Pharma & Biotech
Will Veradermics’ non-hormonal oral pill become the first FDA-approved hair loss therapy in decades?
Veradermics just completed pivotal trial enrollment for VDPHL01, its oral minoxidil for hair loss. Will it reshape dermatology? See what’s next.